Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.
News|Articles|September 18, 2026
FAQ: What retina specialists need to know about the MOGENRY (MCO-010) BLA acceptance
The FDA has accepted Nanoscope's BLA for sonpiretigene isteparvovec in retinitis pigmentosa, backed by RESTORE and REMAIN trial data.
Advertisement
Advertisement
The US Food and Drug Administration has
Related to this article
Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.
FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.
CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.
Prevent Blindness marks IED Week, October 19 to 25, as new therapies and pivotal trials reshape care for uveitis and thyroid eye disease.
Lambert-Eaton myasthenic syndrome is a rare autoimmune disorder of the neuromuscular junction that should be differentiated from myasthenia gravis, another neuromuscular junction disorder.
Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.
AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements.
Advertisement
Advertisement